Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by delivery of CTLA4 and PD1 or PDL1 antibodies combination through CT-guided intra-tumor (IT) injection.

Trial Details

NCT ID

NCT06492408

Phase

PHASE2

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab

Locations (sample)

Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

Histologically or cytologically confirmed previously untreated hepatocellular carcinoma (HCC). If a diagnostic biopsy is available, a pre-treatment…
The patient must be a suitable candidate for surgery, in the opinion of the treating physician.
Signed and dated written informed consent must be provided by the patient prior to admission to the study in accordance with International Conferen…
Eastern Cooperative Oncology Group (ECOG) performance status score 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →